The primary current biomarker model of Alzheimer’s disease (AD) proposes a sequential,non-linear series of pathological changes in which amyloid beta (Aβ) becomes abnormalfirst but does not produce clinical deficits, followed by the spread of tau out of the medialtemporal lobe to wider neocortical regions (Jack,Wiste, et al., 2018;Jack Jr. This evidence concerns the gene MAPT and Alzheimer disease.